date:Dec 14, 2022
Bioscience players Novozymes and Chr. Hansen are merging in a deal that will result in the dissolution of the latter by the fourth quarter of 2023. The new company is expected to post annual revenues upwards of 3.5 billion (US$3.7 billion).
The deal represents the largest merger ever between two Danish companies. Chr. Hansen is a developer of agricultural, pharmaceutical and food ingredients, while Novozymes is the largest provider of microbial technologies and enzymes in the world.
The combin